In The News

Jun 30, 2022 Kazia Therapeutics continues to make good progress on cancer treatment assets

Jun 17, 2022 Kazia Therapeutics secures orphan drug designation for treatment of AT/RT tumours with paxalisib

Jun 14, 2022 Stocks of the Hour: Kazia Therapeutics, Westgold Resources &Lake Resources

Jun 13, 2022 Kazia Therapeutics welcomes presentation of positive paxalisib data at international symposium

Jun 8, 2022 Kazia onto next chapter in Phase 2 brain metastases trial

Jun 7, 2022 Kazia Therapeutics’ Phase 2 paxalisib study moves to expansion stage in breast cancer brain metastases cohort

May 31, 2022 Kazia Therapeutics’ paxalisib now the subject of multi-drug platform study at the University Hospital, Zurich

May 11, 2022 Nasdaq jumps as Dow falls, Immutep, Antisense, Pushpay, AGL, Star on watch: ASX poised to open lower

May 11, 2022 Sector Watch: Healthcare - M&Afever on the cards?

May 5, 2022 Kazia Therapeutics and its flagship asset have made significant progress against brain cancers: Pitt Street Research